Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.
An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity.
Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis.
Primary progressive multiple sclerosis-why we are failing.
Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.
Mycophenolic acid inhibits IL-2-dependent T cell proliferation, but not IL-2-dependent survival and sensitization to apoptosis.
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.
An ADIOL-ERβ-CtBP transrepression pathway negatively regulates microglia-mediated inflammation.
Direct immunomodulatory influence of IFN-β on human astrocytoma cells.
The pathology of acute disseminated encephalomyelitis produced experimentally in the rhesus monkey and its resemblance to human demyelinating disease.
T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis.
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system.
Gender-specific expression of beta1 integrin of VLA-4 in myelin basic protein-primed T cells: implications for gender bias in multiple sclerosis.
Brief International Cognitive Assessment for MS (BICAMS): international standards for validation.
Fcγ receptors in Norwegian multiple sclerosis patients and healthy controls.
Population pharmacokinetics and pharmacodynamics of dalfampridine-ER in healthy volunteers and in patients with MS.
FP187 – Oral Immunomodulatory Dimethyl Fumarate (DMF)
Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study.
Viral triggers of multiple sclerosis.
Mycophenolate mofetil for relapsing-remitting multiple sclerosis.
Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β-1a.
Improving the translational hit of experimental treatments in multiple sclerosis.
Gender as risk factor for autoimmune diseases.

Pages